ArticleTreatment of Negative Symptoms in SchizophreniaRado, Jeffrey T. MDEditor(s): Janicak, Philip G. MD, Editor Author Information Dr. Rado is Assistant Professor of Psychiatry and Internal Medicine, Rush University Medical Center, 2150 West Harrison, Chicago, IL 60612; E-mail: [email protected]. Formerly Frank Ayd's International Drug Therapy Newsletter Dr. Rado has disclosed that he is/was the recipient of grant/research support from Lilly, Otsuka, and Neuronetics and is/was a speaker for Lilly. He has also disclosed that the use of armodafanil, atomoxetine, buspirone, citalopram, electroconvulsive therapy, escitalopram, fluoxetine, galantamine, lamotrigine, memantine, mianserin, minocycline, mirtazapine, modafinil, omega fatty acids, raloxifene, reboxetine, ritanserin, sertraline, sildenafil, transcranial magnetic stimulation, trazadone, and valproate for treatment of schizophrenia as discussed in this article has not been approved by the U.S. Food and Drug Administration. Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on April 30, 2012. Psychopharm Review: May 2011 - Volume 46 - Issue 5 - p 33-39 doi: 10.1097/01.IDT.0000396484.87192.42 Buy CME Test Metrics © 2011 Lippincott Williams & Wilkins, Inc.